MK-0616 : an oral PCSK9 inhibitor for hypercholesterolemia treatment
INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide. Lowering LDL-cholesterol, by lifestyle modification or therapeutically, reduces the risk of ASCVD. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein which binds to the LDL-receptor and induces degradation, is a clinically validated target to lower LDL-cholesterol. Injectable PCSK9 inhibitor therapies have demonstrated substantial reductions in LDL-cholesterol with associated decreased risk of ASCVD events.
AREAS COVERED: MK-0616 is an orally bioavailable, renally excreted, macrocyclic peptide inhibitor of PCSK9. The article provides an understanding of the chemistry and development, pharmacokinetic and pharmacodynamic characteristics of MK-0616 and insight into its clinical efficacy and safety. In clinical trials, MK-0616 produced dose-dependent reductions in LDL-cholesterol, non-HDL-cholesterol, and apolipoprotein (apo) B levels. Furthermore, MK-0616 modestly lowered lipoprotein (a) [Lp(a)].
EXPERT OPINION: MK-0616 is a potent, oral macrocyclic peptide inhibitor of PCSK9 that is not only able to reduce LDL-cholesterol, non-HDL-cholesterol, and apoB, but can also lower Lp(a). Safety and tolerability studies reported to date are promising. MK-0616 may offer advantages over injectable anti-PCSK9 therapies in terms of ease of dosing, patient preference and cost. The results from phase III trials of MK-0616 on cardiovascular outcomes are awaited with interest.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
---|---|
Enthalten in: |
Expert opinion on investigational drugs - 32(2023), 10 vom: 10. Juli, Seite 873-878 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Burnett, John R [VerfasserIn] |
---|
Links: |
---|
Themen: |
97C5T2UQ7J |
---|
Anmerkungen: |
Date Completed 07.11.2023 Date Revised 07.11.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/13543784.2023.2267972 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM363084959 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM363084959 | ||
003 | DE-627 | ||
005 | 20231226092611.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/13543784.2023.2267972 |2 doi | |
028 | 5 | 2 | |a pubmed24n1210.xml |
035 | |a (DE-627)NLM363084959 | ||
035 | |a (NLM)37815341 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Burnett, John R |e verfasserin |4 aut | |
245 | 1 | 0 | |a MK-0616 |b an oral PCSK9 inhibitor for hypercholesterolemia treatment |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.11.2023 | ||
500 | |a Date Revised 07.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide. Lowering LDL-cholesterol, by lifestyle modification or therapeutically, reduces the risk of ASCVD. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein which binds to the LDL-receptor and induces degradation, is a clinically validated target to lower LDL-cholesterol. Injectable PCSK9 inhibitor therapies have demonstrated substantial reductions in LDL-cholesterol with associated decreased risk of ASCVD events | ||
520 | |a AREAS COVERED: MK-0616 is an orally bioavailable, renally excreted, macrocyclic peptide inhibitor of PCSK9. The article provides an understanding of the chemistry and development, pharmacokinetic and pharmacodynamic characteristics of MK-0616 and insight into its clinical efficacy and safety. In clinical trials, MK-0616 produced dose-dependent reductions in LDL-cholesterol, non-HDL-cholesterol, and apolipoprotein (apo) B levels. Furthermore, MK-0616 modestly lowered lipoprotein (a) [Lp(a)] | ||
520 | |a EXPERT OPINION: MK-0616 is a potent, oral macrocyclic peptide inhibitor of PCSK9 that is not only able to reduce LDL-cholesterol, non-HDL-cholesterol, and apoB, but can also lower Lp(a). Safety and tolerability studies reported to date are promising. MK-0616 may offer advantages over injectable anti-PCSK9 therapies in terms of ease of dosing, patient preference and cost. The results from phase III trials of MK-0616 on cardiovascular outcomes are awaited with interest | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a ApoB | |
650 | 4 | |a LDL-cholesterol | |
650 | 4 | |a Lp(a) | |
650 | 4 | |a MK-0616 | |
650 | 4 | |a PCSK9 | |
650 | 4 | |a PCSK9 inhibitor | |
650 | 4 | |a non-HDL-cholesterol | |
650 | 7 | |a PCSK9 protein, human |2 NLM | |
650 | 7 | |a EC 3.4.21.- |2 NLM | |
650 | 7 | |a Proprotein Convertase 9 |2 NLM | |
650 | 7 | |a EC 3.4.21.- |2 NLM | |
650 | 7 | |a Cholesterol, LDL |2 NLM | |
650 | 7 | |a Cholesterol |2 NLM | |
650 | 7 | |a 97C5T2UQ7J |2 NLM | |
650 | 7 | |a Peptides |2 NLM | |
700 | 1 | |a Hooper, Amanda J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g 32(2023), 10 vom: 10. Juli, Seite 873-878 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
773 | 1 | 8 | |g volume:32 |g year:2023 |g number:10 |g day:10 |g month:07 |g pages:873-878 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2023.2267972 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 32 |j 2023 |e 10 |b 10 |c 07 |h 873-878 |